J&J sets the tone for Q1 earnings with strong oncology growth

April 15, 2026

Pharmaceutical Technology

Off the back of J J’s positive Q1, CEO Joaquin Duato forecasts strong growth acceleration for 2026, driven partially by psoriasis med Icotyde